Oral probiotics for the secondary prevention of vulvovaginal infections in pregnant women-double-blind, randomized, placebo-controlled study

During pregnancy, abnormal vaginal flora (AVF), bacterial vaginosis (BV), and vulvovaginal candidiasis (VVC) are associated with serious complications discomfort. We aimed to elucidate the effectiveness of oral probiotics in secondary prevention BV/AVF VVC pregnant women. A multicenter prospective randomized, double blind, placebo controlled trial was conducted at three medical centers between 2016 2021. Women who complained on symptoms positive smear for AVF/BV or candida were treated antibiotics antimycotic agent, respectively. Following normal repeated smear, women divided into a research group, receiving 2 capsules/day probiotic formula containing Bifidobacteriumbifidum, Bifidobacteriumlactis, Lactobacillus (L) acidophilus, L. paracasei, rhamnosus Streptococcus thermophilus ( >6X109/capsule), control (2 capsules/day) until delivery. At least once month following complaints taken assess flora. If positive, Eradication assessed by smear. Vaginal colonization specific lactobacilli from capsules detected using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI TOF-MS).The primary outcome rate developed any infection (BV/AVF/VVC) during study period Twenty-three 24 analyzed cohorts, Baseline characteristics presented table 1. There no difference cohorts (11 (48%) versus 16 (67%), respectively; P=0.19; 2). No woman capsule. Oral product tested this did not colonized vagina reduce women.View Large Image Figure ViewerDownload Hi-res image Download (PPT)